Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Financings

Organigram Extends Innovation Investment with Phylos

By The Northwire Desk — AI Analysis Dec 31, 2025 · 06:00 OGI · 2.32 ORGANIGRAM GLOBAL INC.
OGI · Price

Executive Summary

  • Organigram Global Inc. announced a US$3 million top‑up to its existing loan to Phylos Bioscience, bringing the total loan principal to US$10 million, with maturity on May 25 2028.
  • The amendment grants Organigram five‑year exclusive rights to selected autoflower cannabis genetics in multiple international markets and priority access to a pipeline of 30 new next‑generation seed cultivars delivered twice annually through 2030.
  • The investment secures an enhanced seed‑based cultivation strategy, providing operational security, product differentiation and growth potential in both recreational and medical markets.

Key Details

  • Financing: Additional US$3 million advance under amended loan agreement; combined principal now US$10 million; loan matures 25 May 2028; convertible or otherwise resolvable per amendment terms.
  • Exclusive Rights: Five‑year exclusivity on Organigram’s chosen autoflower cultivars across Canada, Australia, the UK, Germany, Israel, with ability to add further territories.
  • Seed Pipeline: Commitment to deliver 30 new next‑generation genetics twice a year through 2030, supporting both recreational and medical product lines.
  • Strategic Benefit: Provides Organigram priority access to Phylos’ autoflower genetics pipeline, preferential economic terms, and long‑term international market rights, enhancing operational security and scalability of seed‑based cultivation.
  • Quotes:
  • Borna Zlamalik (SVP Innovation & International R&D, Organigram): Emphasized seed‑based cultivation as a key advantage delivering consistency, scalability and economic benefit.
  • Ralph Risch (CEO, Phylos): Highlighted the investment’s role in accelerating development of new traits and F1 hybrid seeds, giving Organigram an economic edge.

Notable Quotes

  • “Seed-based cultivation has become a key advantage of Organigram’s cultivation strategy, giving us unprecedented consistency, scalability, and economic benefit.” – Borna Zlamalik
  • “Their investment allows Phylos to accelerate development of new traits and F1 hybrid seeds, while giving Organigram a meaningful economic advantage as the first to deploy those innovations at commercial scale.” – Ralph Risch
Read the original news release →

More from ORGANIGRAM GLOBAL INC.

May 14, 2026 · 08:45

Organigram Left Watching as European Cannabis Boom Accelerates, Q2 Miss Deepens Share Slide

M&A / Property May 12, 2026 · 06:00

Organigram’s core Canadian business stumbles into the red just as its landmark Sanity Group deal closes, leaving investors to wonder if the European cure will be enough to offset domestic decay.

Earnings Apr 15, 2026 · 12:03

Organigram Executes Europe Pivot as BAT Deal Closes, Dilution Looms

Financings Mar 30, 2026 · 20:30

Organigram Clears Final Hurdle for Sanity Acquisition as Dilution and Cash Constraints Loom

Financings Mar 23, 2026 · 14:07

Organigram garners ISS support for Sanity transaction

M&A / Property Mar 23, 2026 · 06:00

Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH

M&A / Property